Welcome to our dedicated page for Vyne Therapeutics SEC filings (Ticker: VYNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for VYNE Therapeutics Inc. (VYNE) provides direct access to the company’s regulatory disclosures as a Nasdaq-listed clinical-stage biopharmaceutical issuer. These documents include annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, which together outline VYNE’s financial condition, risk factors, clinical programs and material corporate events.
Through its filings, VYNE describes its focus on developing differentiated BET inhibitor therapies for chronic inflammatory and immune-mediated conditions, including programs such as the oral BD2-selective BET inhibitor VYN202 and the topical pan-BD BET inhibitor repibresib gel. Periodic reports discuss research and development spending, general and administrative expenses, royalty revenue from its agreement with LEO Pharma A/S for Finacea® foam, and cash runway expectations under various operating assumptions.
Current reports on Form 8-K highlight specific developments that may be important to investors. Examples include disclosures of quarterly and annual financial results, clinical trial updates that are furnished as exhibits, and governance changes such as director resignations. A notable Form 8-K filed on December 17, 2025 describes VYNE’s entry into an Agreement and Plan of Merger and Reorganization with Yarrow Bioscience, Inc. and a merger subsidiary. That filing summarizes the structure of the all-stock merger, the expected pro forma ownership split, planned stockholder approvals, and conditions to closing, as well as related financing arrangements and support agreements.
Other 8-K filings detail the company’s annual meeting voting results and confirm its continued listing of common stock on The Nasdaq Stock Market LLC under the symbol VYNE. Together, these filings allow readers to review how VYNE reports material events, manages its capital structure and describes its strategic review and merger plans.
On this page, AI-powered tools can help interpret complex sections of lengthy filings by highlighting key points, summarizing risk factor themes and explaining the implications of items such as merger agreements, clinical program disclosures and changes in governance. Users can quickly locate information about VYNE’s quarterly performance in Forms 10-Q, its annual overview and risk disclosures in Form 10-K, and specific events reported on Forms 8-K, while using AI-generated summaries as a guide to the underlying regulatory text.
VYNE Therapeutics Chief Financial Officer Zeronda Tyler reported an automatic tax-related share disposition. On the vesting of restricted stock units, 4,007 shares of common stock were withheld by the company at $0.5975 per share to cover tax obligations. After this non-market transaction, Tyler directly holds 99,788 shares of VYNE common stock.
VYNE Therapeutics Inc.'s Chief Scientific Officer Stuart Iain reported a routine tax-related share disposition. On the vesting of restricted stock units, 2,876 shares of common stock were withheld by the company to satisfy tax withholding requirements at an indicated value of $0.5975 per share. After this non-market transaction, he directly holds 112,363 common shares, so the withholding reflects only a small portion of his overall position.
VYNE Therapeutics Inc. chief legal officer Harsch Mutya reported a tax-related share disposition. On the vesting of restricted stock units, 4,007 shares of common stock were withheld by the company at $0.5975 per share to satisfy tax withholding requirements.
After this withholding, Mutya directly holds 121,898 shares of VYNE common stock. The transaction is classified as a tax-withholding disposition rather than an open-market sale.
VYNE Therapeutics President and CEO David Domzalski had 14,232 shares of Common Stock withheld on March 31, 2026 to cover tax obligations from vesting restricted stock units. This was a tax-withholding disposition at $0.5975 per share, and he continues to hold 401,976 shares directly.
VYNE Therapeutics Inc. proposes to issue VYNE common stock and pre-funded warrants as part of a merger with Yarrow Bioscience, Inc., pursuant to an Agreement and Plan of Merger and Reorganization dated December 17, 2025 (as amended). The filing sets an estimated exchange ratio of approximately 35.8667 VYNE shares per Yarrow share and describes a Yarrow pre-closing financing of approximately $100 million.
The proxy/prospectus explains treatment of options, assumed pre-funded warrants, a planned pre-closing cash dividend of about $14.5 million to $16.5 million, director and executive interests, support and lock-up agreements, Nasdaq initial listing expectations, and accounting as an in-substance reverse recapitalization (Yarrow as accounting acquirer). Proposals needing VYNE stockholder approval include issuance of shares under Nasdaq rules and a reverse stock split.
VYNE Therapeutics Inc. received an extension from Nasdaq to regain compliance with its minimum bid price listing rule. The company had previously failed to lift its common stock closing bid price back to at least $1.00 for 30 consecutive business days by March 10, 2026.
Nasdaq granted VYNE an additional 180 days, until September 7, 2026, to meet the $1.00 minimum bid price requirement. VYNE’s stock will continue trading on the Nasdaq Capital Market under the symbol “VYNE” during this period, and the company is considering options such as a potential reverse stock split to restore compliance.
VYNE Therapeutics’ annual report centers on a planned reverse-merger with Yarrow Biosciences that would effectively hand control to Yarrow investors. Pre‑Merger VYNE stockholders are expected to own about 3% of the combined company, with Yarrow holders owning about 97%, and VYNE would be renamed Yarrow Bioscience, Inc.
Yarrow investors have committed $100 million of Series A preferred equity and a further $100 million of common stock or pre‑funded warrants, all converting into VYNE securities at closing. VYNE plans a special cash dividend of roughly $14.5–$16.5 million to its pre‑Merger stockholders and warrant holders.
The report also details VYNE’s BET inhibitor platform, including discontinuation of its Phase 2b repibresib gel vitiligo trial after missing the primary endpoint, and early Phase 1b psoriasis data for oral BD2‑selective BET inhibitor VYN202, which showed clinical and biomarker improvements but faces a partial FDA clinical hold due to testicular toxicity findings in dogs. A repeat toxicology study in male dogs began in October 2025, with completion expected in the second half of 2026. If the Yarrow merger fails, the board may seek another strategic transaction or consider liquidation.
VYNE Therapeutics has amended its merger agreement with Yarrow Bioscience and Yarrow Merger Sub. The change lets certain Yarrow stockholders receive pre-funded warrants instead of VYNE common shares that would push them above a specified beneficial ownership limit, while preserving their right to obtain the excess shares by exercising the warrants.
The amendment also clarifies that the Parent Pre-Closing Dividend may be paid not only on VYNE common stock outstanding but also on shares underlying specified outstanding VYNE warrants, in each case as of the dividend record date. VYNE plans to file a Form S-4 with a proxy statement/prospectus containing further details on the proposed transaction.
VYNE Therapeutics Inc. amended its merger agreement with Yarrow Bioscience to adjust how equity is delivered to Yarrow stockholders at closing. If a holder would exceed a specified beneficial ownership cap, VYNE may instead issue pre-funded warrants allowing later purchase of the remaining entitled VYNE common shares.
The amendment also clarifies that the planned Parent Pre-Closing Dividend can be paid to holders of VYNE common stock and to holders of certain VYNE warrants, based on the VYNE shares underlying those warrants as of the dividend record date.
VYNE Therapeutics agreed to merge with privately held Yarrow Bioscience, with Yarrow becoming a wholly owned subsidiary in a stock-for-stock deal intended to be tax-free. Based on the expected share exchange, pre‑merger Yarrow stockholders are projected to own about 97% of the combined company, while current VYNE stockholders would own about 3%.
Before closing, VYNE expects to pay its existing stockholders a cash dividend of approximately $14.5–$16.5 million in total and accelerate vesting of its stock options and restricted stock units, with in‑the‑money options cashed out at the merger price. Yarrow has raised about $100 million in a Series A preferred round and lined up an additional $100 million PIPE financing. The deal, which requires shareholder approvals, Nasdaq listing and SEC registration statement effectiveness, is expected to close in the second quarter of 2026, after which Yarrow will control the board and management.